Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab or JNJ-40346527 in high-risk localized prostate cancer
NCT03177460Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2017
- Primary completion
- Jan 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of daratumumab and edicotinib in prostate adenocarcinoma, sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2017; status: completed.
02
Drugs
daratumumabedicotinib
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT03177460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03177460.